Veregen sinecatechins regulatory update
Medigene said Israel, Denmark and Slovakia approved Veregen sinecatechins to treat genital warts. The topical formulation of polyphenols extracted from green tea leaves is already approved in the U.S., Germany, Austria, Switzerland, Spain, France, Sweden and Norway, with additional approvals in the EU expected "within the next few months." Medigene said partner Azanta A/S (Hellerup, Denmark) expects to launch the drug in Denmark, Norway and Sweden early next year, while partner Teva Pharmaceutical Industries Ltd. (NYSE:TEVA, Petah Tikva, Israel) expects to launch the product in Israel next year. Azanta has exclusive rights to market Veregen in Denmark, Sweden, Norway, Finland and Iceland under a June deal, while Teva has exclusive rights to market the product in Israel under a 2010 deal (see BioCentury, March 1, 2010 & June 18, 2012). ...